Program
rotigotine
Also written as “Rotigotine”, “SPM 962” and “Rotigotine transdermal patch”.
Its studies are mostly in Parkinson Disease · Restless Legs Syndrome · Fibromyalgia, led by 5 companies.
Drug pageRotigotine: every studyMany companies study it; this page follows only the 63 they lead. All 77 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| UCBits history only | 500 open or running | phase 4since Dec 21, 2007 | Aug 24, 2005 | none ahead |
| Otsuka | 100 open or running | phase 3since Sep 27, 2007 | Sep 27, 2007 | none ahead |
| Eva Pharmaits history only | 11 open or running | no phasesince May 30, 2025 | May 30, 2025 | none ahead |
| Inflamax Researchits history only | 10 open or running | phase 1since Feb 25, 2016 | Feb 25, 2016 | none ahead |
| Luye Pharma Groupits history only | 10 open or running | phase 1since Mar 31, 2016 | Mar 31, 2016 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Otsuka only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 27, 2007First study: phase 3 study in Parkinson DiseaseFirst studyNCT00537485 · 180 enrolled · Japan
- Apr 23, 2008Phase 2 study in Idiopathic Restless Legs SyndromeNCT00666965 · 230 enrolled · Japan
- Mar 4, 2010Phase 3 study in Idiopathic Restless Legs SyndromeNCT01084551 · 284 enrolled · Japan
- Mar 22, 2012Phase 2 study in Idiopathic Restless Legs SyndromeNCT01562743 · 185 enrolled
- Jun 24, 20123 phase 3 studies in Parkinson DiseaseNCT01628926, NCT01631825, NCT01628965
- Jun 24, 20123 phase 2 studies in Parkinson DiseaseNCT01628848, NCT01631812, NCT01634243
TargetBeta
“D2-like dopamine receptor agonist”ChEMBL 37, by rule
Other programs on the same three targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Olanzapinerule | Eli Lilly | phase 4 | 76 |
| Pramipexolerule | Boehringer Ingelheim | phase 4 | 44 |
Studies
All 10 Otsuka leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT01634243Parkinson Disease · Japan | 2 | Completed | May 2006 | 64 |
| NCT01631825Parkinson Disease · Japan | 3 | Completed | Jun 2012 | 321 |
| NCT01631812Parkinson Disease · Japan | 2 | Completed | Feb 2010 | 130 |
| NCT01628965Parkinson Disease · Japan | 3 | Completed | Oct 2010 | 143 |
| NCT01628926Parkinson Disease · Japan | 3 | Completed | May 2011 | 420 |
| NCT01628848Parkinson Disease · Japan | 2 | Completed | Apr 2008 | 174 |
| NCT01562743Idiopathic Restless Legs Syndrome | 2 | Completed | Oct 2010 | 185 |
| NCT01084551Idiopathic Restless Legs Syndrome · Japan | 3 | Completed | Sep 2011 | 284 |
| NCT00666965Idiopathic Restless Legs Syndrome · Japan | 2 | Completed | Aug 2009 | 230 |
| NCT00537485Parkinson Disease · Japan | 3 | Completed | Dec 2009 | 180 |
How it is read
Names in the registry
- “Rotigotine”, 39 entries
- “SPM 962”, 13 entries
- “Rotigotine transdermal patch”, 4 entries
- “Rotigexole 8 mg”, 1 entry
- “Rotigotine 1 mg/24 h”, 1 entry
Conditions, from the studies’ own filings
- Parkinson Disease, 38 studies
- Restless Legs Syndrome, 17 studies
- Fibromyalgia, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.